Drug and pharmaceutical recalls

Subpotent Drug

Subpotent Drug

Subpotent Drug

Due to an out-of-specification result for an unidentified impurity detected during routine stability testing.

July 24, 2026 - Taoyuan City, Taiwan - Sunny Pharmtech, Inc is voluntarily recalling three lots of Cyclophosphamide for Injection, USP, 1g/vial and 2g/vial, to the User Level due to the presence of particulate matter identified as steel. To date, no adverse events or injuries associated with this pa

July 24, 2026 – DEERFIELD, Ill., Baxter International Inc. (NYSE:BAX) is voluntarily recalling Lot LD175708, Exp 14-Feb 2027 of Cefazolin in Dextrose Injection due to a report of particulate matter found in the solution identified as cardboard.<br> Risk Statement: The use of the defective product has a

July 24, 2026 – Shirley, NY, American Regent, Inc. is conducting a nationwide voluntary recall of a single lot of Papaverine Hydrochloride Injection, USP, 60 mg/2 mL single dose vial to the consumer level. The product is being recalled due to the presence of particulate matter identified as glass an

Lack of Assurance of Sterility: Affected product may exhibit an open or incomplete seal on the packaging of the applicator

Lack of Assurance of Sterility

SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

Subpotent Drug: Low out of specification assay results performed during long-term stability testing.

Relay Peak Research LLC (Zen Principle Naturals) of Incline Village, NV is voluntarily recalling its Zen Principle® brand Moringa Capsules dietary supplement because the product has the potential to be contaminated with Salmonella, an organism which can cause serious and sometimes fatal infections i

FOR IMMEDIATE RELEASE – July 18th, 2026 – Panoli, Gujarat, Unique Pharmaceutical Laboratories (A Div. of J. B. Chemicals &amp; Pharmaceuticals Ltd.) is voluntarily recalling four lots of Cetirizine Hydrochloride Tablets USP 5 mg to the consumer level due to cross contamination with Ranitidine.

cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).

cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).

cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).

Labeling: Label Mix-up: Capsules contain only immediate-release (IR) pellets while labeled as ER capsules.

Lack of Assurance of Sterility

Lack of Assurance of Sterility

CGMP Deviations: An incorrect detergent was used and the required swab sampling was not performed on a production hopper that had previously been used for a different product.